At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 108 enrolled
Drug / intervention
Hylan GF-20 alone +1 moredrug
Likely dose
Hylan GF-20 alone 6mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective And Randomized Study Evaluating Tthe Effect Of The Association Of Triamcinolone To The Viscosupplementation Of The Knee
In Brief
A Phase 4 clinical trial evaluating Hylan GF-20 alone and Triamcinolone for Osteoarthritis. Completed, enrolled 108 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate if the investigators can achieve better early outcomes adding triamcinolone to the viscosupplementation procedure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesBrazil
CollaboratorsFundação de Amparo à Pesquisa do Estado de São Paulo
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedApr 2011
Primary CompletionNov 2011
Study CompletionJul 2012
TodayJul 2026
First PostedApr 14, 2011
Enrollment StartMar 1, 2011
Primary CompletionNov 1, 2011
Study CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.2 years ago
Interventions
Hylan GF-20 alonedrug
A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)
Triamcinolonedrug
A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)